臺灣博碩士論文加值系統

惡性程度較高的癌細胞通常表現出較高的浸襲力，抗無貼附狀態細胞凋亡、血管新生及遠端轉移能力。一些CCN家族或成員已被報導可調控上述表現型，結締組織生長因子於正常肺膜上皮細胞表現量相當高，本論文在探究結締組織生長因子是否介入調控人類細胞轉移的能力。
過度表現結締組織生長因子於CL1-5及A549的人類肺腺癌細胞株能有意義地降低癌細胞的浸襲力及遠端肺轉移率，在結締組織生長因子轉殖株中，神經塌陷因子呈現有意義的上升。加入integrin αvβ3及αvβ5抑制劑能阻斷結締組織生長子造成的神經塌陷因子上升現象，而處理神經塌陷因子的反核數序列株，則可回復因結締組織生長因子造成的浸襲力降低。實驗中發現，單獨使用結締組織生長因子的CT功能區段便能造成神經塌陷因子增加，並有效抑制肺癌細胞的浸襲。臨床上分析結締組織生長因子蛋白表現量較低的病人，與癌病惡性度較高，有淋巴轉移，較早癌病復發率及較短存活時間有正相關。因為癌細胞轉移的第一個步驟是自原病灶脫離，而能與血路中存活，我們分析結締組織生長因子是否也在此步驟中扮演促進細胞凋亡的角色，而造成轉移的抑制。在第三章中，我們分析高表現結締組織生長因子的肺癌細胞株，對無貼狀態引起的細胞凋亡較明顯，而內生性的死亡相關蛋白量也較高。
在結締組織生長因子轉殖株中，死亡相關蛋白呈現有意義的上升，實驗中發現若轉殖死亡相關蛋白反序列質體入結締組織生長因子轉殖株，則可降低因無貼附狀態而誘發的細胞凋亡現象，且是經由抑制了ERK/Elk-1之訊息傳遞路徑，如同第二章的結果，只需CT區段的結締組織生長因子便能有效造成死亡相關蛋白的上升，而造成無貼附狀態的肺癌細胞株細胞凋亡。
根據之前的實驗結果，肺癌細胞病人腫瘤大小與結締組織生長因子的表現量有反相關，於是在第四章中，我們試圖探究結締組織生長因子與腫瘤發生及血管新生的關係。病患切片中可見高結締組織生長因子表現量的檢體，血管內皮生長因子及微血管的數量則明顯較低。細胞離體實驗則證明，結締組織生長因子蛋白能抑制血管內皮生長因子及缺氧誘發因子的蛋白及傳訊RNA的表現量。我們亦進行動物腫瘤生長及血管新生實驗來證明結締組織生長因子確能抑制血管新生現象，作用是藉由活化ARD1造成缺氧誘發因子基因的乙醯化，而使該蛋白趨向不穩定所致。
總結來說，本論文提供了結締組織生長因子可抑制人類肺腺癌轉移及血管新生的證據；作為一個癌細胞浸襲抑制蛋白，無貼附狀態細胞凋亡促進者，及血管新生抑制蛋白，結締組織生長因子作為臨床治療的蛋白質類藥物，是相當具潛力而可期待的。

Advanced cancer cells show higher invasive, anti-anoikis, angiogenesis, and metastatic abilities. Several members of CCN [CTGF (connective tissue growth factor), Cyr61 (cysteine-rich 61), Nov (nephroblastoma overexpressed)] family can modulate these phenotypes of human carcinoma. CTGF is highly expressed in normal lung epithelium. We investigated the possibility that CTGF may regulate human lung adenocarcinoma metastasis activities.
Overexpression of CTGF in CL1-5 and A549 cells decreased invasiveness and lung metastasis relative to control cells. CTGF-mediated CRMP-1 (collapsin response mediator protein-1) up-regulation was also noted in CTGF transfected clones, and was inhibited by anti-integrin AvB3 and AvB5 antibodies. Significantly, suppression of CRMP-1 expression by antisense oligonucleotides increased invasive ability. We also clarified the CT domain of CTGF as the major component responsible for CRMP-1 up-regulation and invasion inhibition. Immunohistochemistry of lung cancer specimens showed that reduced expression of CTGF was statistically significantly associated with advanced disease, lymph node metastasis, early postoperative relapse, and shorter survival.
Because the first step of metastasis is to detach from the primary tumor mass and survive in the bloodstream, we analyzed several lung cancer cell lines which expressed different levels of CTGF undergo apoptosis in anoikis condition in order to understand whether CTGF is involved in anoikis regulation. In the chapter 3, we demonstrated that highly CTGF expressed cells showed increased sensitivity to anoikis, and were correlated with the expression of DAPK (death associated protein kinase), a newly identified protein kinase associated with apoptosis. We further found DAPK is upregulated in CTGF-overexpressed clones, and transiently transfected dominant-negative DAPK diminished DNA fragmentation after detachment in CTGF-overexpressed clones. The CT module of CTGF was also the region primarily responsible for the induction of DAPK via ERK/Elk-1 signaling pathway.
In chapter 4, due to the significant inverse correlation between CTGF expression and tumor size in lung adenocarcinoma patients ( P < 0.041 ), we investigated the angiogenic and tumorigenic potential of CTGF-overexpressed CL1-5 lung adenocarcinoma cells. We identified consistently inverse correlation between CTGF and VEGF (vascular endothelial growth factor) or CD31 staining in cancerous tissue than in adjacent noncancer part in lung adenocarcinoma patient. In vitro study showed that CTGF inhibited VEGF, and HIF-1a (hypoxia-inducible factor) mRNA and protein expression, and decreased HRE (hypoxia-response element) luciferase activities. We further identified that CTGF inhibited in vivo tumor growth and in vitro and in vivo angiogenesis of lung adenocarcinoma cell lines. At molecular level, CTGF inhibited HIF-1a expression via destabilization of HIF-1a by ARD1-mediated acetylation.
In summary, these studies provide evidences for the tumor metastasis suppressing effect of CTGF in the lung adenocarcinoma. Herein, as an invasion blocker, anoikis promoter and angiogenesis inhibitor that specifically targets cancer cells, CTGF has a unique potential for lung adenocarcinoma treatment.

中文摘要 (Abstract in Chinese) 3
英文摘要 (Abstract in English) 5
第一章 序論 (Introduction) 7
第一節 人類肺腺癌 (Human lung adenocarcinoma) 8
第二節 結締組織生長因子 (Connective tissue growth factor) 11
第三節 本論文的研究動機與方向 (Motivation and purpose in the thesis) 13
第四節 參考文獻 (Reference) 14
第二章 結締組織生長因子抑制人類肺腺癌細胞之浸襲及轉移 (Connective tissue growth
factor and its role in lung adenocarcinoma invasion and metastasis) 18
第一節 摘要 (Abstract) 19
第二節 前言 (Introduction) 21
第三節 材料與方法 (Materials and Methods) 23
第四節 實驗結果 (Results) 32
第五節 討論 (Discussion) 40
第六節 參考文獻 (Reference) 45
第七節 附圖及說明 (Figures and figure legends) 51
第三章 結締組織生長因子提高人類肺腺癌細胞對無貼附狀態之細胞凋亡敏感度 (Connective tissue growth factor increased human lung adenocarcinoma cells anoikis sensitivity) 65
第一節 摘要 (Abstract) 66
第二節 前言 (Introduction) 68
第三節 材料與方法 (Materials and Methods) 70
第四節 實驗結果 (Results) 80
第五節 討論 (Discussion) 92
第六節 參考文獻 (Reference) 96
第七節 附圖及說明 (Figures and figure legends) 101
第四章 結締組織生長因子透過促進缺氧誘發因子降解以抑制癌細胞之血管新生 (Connective tissue growth factor inhibited angiogenesis by accelerating HIF-1�� degradation in human lung adenocarcinoma) 119
第一節 摘要 (Abstract) 120
第二節 前言 (Introduction) 122
第三節 材料與方法 (Materials and Methods) 124
第四節 實驗結果 (Results) 132
第五節 討論 (Discussion) 140
第六節 參考文獻 (Reference) 143
第七節 附圖及說明 (Figures and figure legends) 149
結語 (Conclusion) 164
附錄：已發表之論文（Publication list） 165

參考文獻 (Reference)
(1) Peter Carmeliet & Rakesh K. Jain Angiogenesis in cancer and other diseases Nature 2000;407: 249-57.
(2) Peter Carmeliet Mechanisms of angiogenesis and arteriogenesis Nature Medicine 2000;6: 389–95.
(3) Gabriele Bergers, Laura E. Benjamin Angiogenesis: Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 2003;3:401–10.
(4) Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 2000;100: 7–70.
(5) Fukumura D, Xavier R, Sugiura T. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715–25.
(6) Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis (Lond.), 2000;21: 505–15.
(7) Ferrara, N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 2002;29:10–4.
(8) Forsythe, J., Jiang, B-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996;16: 4604–13.
(9) Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med.2002; 8: S62–7.
(10) Yamamoto S, Yasui W, Kitadai Y, Yokozaki H, Haruma K, Kajiyama G, et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int 1998;48:499–506.
(11) Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 1999;125:195–201.
(12) Kido S, Kitadai Y, Hattori N, Haruma K, Kido T, Ohta M, et al. Interleukin 8 and vascular endothelial growth factor—prognostic factors in human gastric carcinomas? Eur J Cancer 2001;37:1482–7.
(13) Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000;6:2803–7.
(14) Bradham DM, Igarashi A, Potter RL, et al. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991;114:1285–94.
(15) Latinkic BV,O’Brien TP,Lau LF. Promoter function and structure of the growth factor-inducible immediate early gene cyr61. Nucleic Acids Res 1991; 19: 3261–7.
(16) Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125–30.
(17) Grotendorst GR. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 171–9.
(18) Moussad EE, Brigstock DR. Connective tissue growth factor: What’s in a name? Mol Genet Metab 2000; 71: 276–92.
(19) Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteinsin tumourigenesis. Cancer Cell Int. 2003 ;3:15.
(20) Shimo T, Nakanishi T, Kimura Y et al. Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J Biochem (Tokyo) 1998; 124: 130–40.
(21) ShimoT, Nakanishi T, Nishida T et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem (Tokyo) 1999; 126: 137–45.
(22) Babic AM,Chen CC,Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999; 19: 2958–66.
(23) Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, Ogawa A, Sawai T. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma Neurol Res. 2002;24(7):677-83.
(24) Inoki I,Shiomi T,Hashimo to G et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002;16: 219–21.
(25) Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277(39):36288-95.
(26) Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003;9:1026-32.
(27) D''Amico TA. Angiogenesis in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2004;16(1):13-8.
(28) Gridelli C. Targeted therapies in the treatment of non small cell lung cancer: reality and hopes. Curr Opin Oncol 2004;16(2):126-9.
(29) Lee JW, Bae SH, Jeong JW, Kim SH, and Kim KW. Hypoxia-inducible factor (HIF-1)a: Its protein stability and biological functions. Exp Mol Med 2004;36(1):1-12.
(30) Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, Chau YP, Yang PC, Kuo ML. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst. 2004;96(5):364-75.
(31) Semenza GL, Jiang BH, Leung SW et al: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem, 1996;271:32529-37.
(32) Jiang BH, Zheng JZ, Leung SW et al: Transactivation and inhibitory domains of hypoxia-inducible factor 1(alpha): modulation of transcriptional activity by oxygen tension. J Biol Chem, 1997;272:19253-60.
(33) Wood SM, Gleadle JM, Pugh CW et al: The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression: studies in ARNT-deficient cells. J Biol Chem, 1996;271:15117-23.
(34) Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003;3:721-32.
(35) Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med, 2000;6”1335-40.
(36) Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther, 2001;8:638-45.
(37) Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-41.
(38) Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111:709-20.
(39) Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-5.
(40) Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF- 1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642-7.
(41) Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 2000;97:4748-53.